A national survey of 157 patients with non-small cell lung cancer found that all groups prioritized extending life, but ...

Because AI chatbots often respond in a sycophantic manner that can mirror and build upon users’ beliefs with little or no disagreement, Morrin said in an interview with Scientific American, the effect ...

In lupus patients, latent Epstein-Barr virus can reprogram B cells and send the body’s immune response into overdrive, resulting in widespread inflammation. The Epstein-Barr virus (EBV) has been ...

Employer healthcare costs continue to rise, with high-cost claims and high drug and hospital prices being the biggest ...

Approximately 80% of cardiovascular disease is preventable through lifestyle modifications and risk factor management, according to the American Heart Association’s “Life's Essential Eight” framework, ...

Patients with statin resistance do not experience symptoms, Le noted. Instead, the problem is that statins do not lower LDL-C levels as much as they typically do. Instead of a 50% reduction, people ...

December 1 is World AIDS Day. First recognized in 1988, it is a day international communities take to remember those who have died from HIV/AIDS and to demonstrate continued support of ongoing efforts ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Kristine Rawlings, PharmD | Authors | Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Health benefit costs for employees are projected to rise 6.7% in 2026—the largest increase in 15 years—as employers grapple with escalating prescription drug prices, growing GLP-1 coverage and a ...

Almost 3,000 managed care pharmacy leaders attended the Academy of Managed Care Pharmacy (AMCP) Nexus meeting, which was held last week at the Gaylord National Resort and Convention Center in National ...

Patients with hidradenitis suppurativa (HS) who started on or switched to biosimilar adalimumab experienced lower treatment success and lost response more quickly, according to an Australian study ...